Literature DB >> 23632183

Inhaled hypertonic saline+hyaluronic acid in cystic fibrosis with asthma-like symptoms: a new therapeutic chance.

Federico Cresta1, Aldo Naselli, Federica Favilli, Rosaria Casciaro.   

Abstract

The aim of the paper is to report the case of a boy affected by cystic fibrosis, with non-ABPA-related recurrent wheezing and frequent pulmonary exacerbation during childhood, who had been  inhaling 7% NaCl+0.1% hyaluronic acid (HA) as a maintenance therapy. We reviewed patient database and, analysing a 7-year follow-up, considered pulmonary exacerbation, antibiotic and steroid courses, pulmonary function (forced expiratory volume in one second; FEV1) and microbiological data. After starting 7% NaCl+0.1% HA treatment, we observed a dramatic decrease of oral antibiotic need (0.55 courses/month during the pretreatment period against 0.10 courses/month in the treatment period), associated with a good initial recovery and a stability of FEV1. In our opinion this case could suggest an extended indication for inhaled 7% NaCl+0.1% HA use in CF, not only in patients who did not tolerate hypertonic saline, but also in patients with coexistent asthma-like symptoms.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23632183      PMCID: PMC3645254          DOI: 10.1136/bcr-2013-009042

Source DB:  PubMed          Journal:  BMJ Case Rep        ISSN: 1757-790X


  10 in total

Review 1.  Hyaluronan in respiratory injury and repair.

Authors:  Gerard M Turino; Jerome O Cantor
Journal:  Am J Respir Crit Care Med       Date:  2003-05-01       Impact factor: 21.405

2.  Inhaled hypertonic saline produces small increases in lung function in patients with cystic fibrosis.

Authors:  Felix Ratjen
Journal:  J Pediatr       Date:  2006-07       Impact factor: 4.406

Review 3.  Molecular mechanisms of CFTR chloride channel dysfunction in cystic fibrosis.

Authors:  M J Welsh; A E Smith
Journal:  Cell       Date:  1993-07-02       Impact factor: 41.582

4.  Inhaled hyaluronic acid against exercise-induced bronchoconstriction in asthma.

Authors:  L I Z Kunz; E L J van Rensen; P J Sterk
Journal:  Pulm Pharmacol Ther       Date:  2005-09-01       Impact factor: 3.410

Review 5.  Inhaled hypertonic saline as a therapy for cystic fibrosis.

Authors:  Mark R Elkins; Peter T P Bye
Journal:  Curr Opin Pulm Med       Date:  2006-11       Impact factor: 3.155

6.  Failure to recover to baseline pulmonary function after cystic fibrosis pulmonary exacerbation.

Authors:  Don B Sanders; Rachel C L Bittner; Margaret Rosenfeld; Lucas R Hoffman; Gregory J Redding; Christopher H Goss
Journal:  Am J Respir Crit Care Med       Date:  2010-05-12       Impact factor: 21.405

7.  Hyaluronic acid improves "pleasantness" and tolerability of nebulized hypertonic saline in a cohort of patients with cystic fibrosis.

Authors:  Paolo Buonpensiero; Fabiola De Gregorio; Angela Sepe; Antonio Di Pasqua; Pasqualina Ferri; Maria Siano; Vito Terlizzi; Valeria Raia
Journal:  Adv Ther       Date:  2010-10-14       Impact factor: 3.845

8.  Severe small airways disease resistant to medical treatment in a child with cystic fibrosis.

Authors:  J Davies; M Rosenthal; A Bush
Journal:  J R Soc Med       Date:  1996-03       Impact factor: 5.344

9.  Hyaluronan blocks human neutrophil elastase (HNE)-induced airway responses in sheep.

Authors:  Mario Scuri; William M Abraham
Journal:  Pulm Pharmacol Ther       Date:  2003       Impact factor: 3.410

10.  Mechanisms of bronchial hyperreactivity in cystic fibrosis.

Authors:  P P Van Asperen; P Manglick; H Allen
Journal:  Pediatr Pulmonol       Date:  1988
  10 in total
  5 in total

1.  Pathological Hyaluronan Matrices in Cystic Fibrosis Airways and Secretions.

Authors:  Brittany Matuska; Suzy Comhair; Carol Farver; James Chmiel; Ronald J Midura; Tracey Bonfield; Mark E Lauer
Journal:  Am J Respir Cell Mol Biol       Date:  2016-10       Impact factor: 6.914

Review 2.  Hyaluronan as a therapeutic target in human diseases.

Authors:  Jiurong Liang; Dianhua Jiang; Paul W Noble
Journal:  Adv Drug Deliv Rev       Date:  2015-11-02       Impact factor: 15.470

Review 3.  Modulation of hyaluronan signaling as a therapeutic target in human disease.

Authors:  Stavros Garantziotis
Journal:  Pharmacol Ther       Date:  2021-09-26       Impact factor: 12.310

Review 4.  The Rise and Fall of Hyaluronan in Respiratory Diseases.

Authors:  Mark E Lauer; Raed A Dweik; Stavros Garantziotis; Mark A Aronica
Journal:  Int J Cell Biol       Date:  2015-09-10

Review 5.  Size Matters: Molecular Weight Specificity of Hyaluronan Effects in Cell Biology.

Authors:  Jaime M Cyphert; Carol S Trempus; Stavros Garantziotis
Journal:  Int J Cell Biol       Date:  2015-09-10
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.